to market our RenalGuard
product, the clinical trials for that product may not be successful, the
RenalGuard product may not be commercially accepted, operational changes,
competitive developments may affect the market for our products, regulatory
approval requirements may affect the market for our products, and
additional risk factors described in our Report on Form 10-Q for the
quarter ended September 30, 2007, and our other SEC reports.
PLC Systems, PLC Medical Systems, PLC and CO2 Heart Laser, RenalGuard,
RenalGuard Therapy and RenalGuard System are trademarks of PLC Systems Inc.
Novadaq and SPY are trademarks of Novadaq Technologies, Inc.
Edwards Lifesciences is a trademark of Edwards Lifesciences Corporation.
PLC SYSTEMS INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
Three Months Ended Year Ended
December 31, December 31,
2007 2006 2007 2006
Product sales $ 935 $1,400 $ 4,564 $ 5,662
Service fees 313 347 1,440 1,484
Total revenues 1,248 1,747 6,004 7,146
Cost of revenues:
Product sales 423 544 1,829 2,031
Service fees 175 185 806 701
Total cost of revenues 598 729 2,635 2,732
Gross profit 650 1,018 3,369 4,414
Selling, general and
administrative 875 544 3,794 3,014
Research and development 698 539 2,382 1,924
expenses Page: 1 2 3 4 5 6 Related medicine technology :1
. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial2
. PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)3
. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial4
. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System5
. Imaging Diagnostic Systems CTLM Technology Presented at Congress of World Society for Breast Health6
. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB7
. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 20078
. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials9
. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System10
. NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit11
. PA Department of Health Reports Rise in Flu Activity; Reminds Public of Need for Flu Shot